Concepedia

Sandra Koseoglu

SK

10

Publications

582

Citations

10

H-Index

2002

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Sandra Koseoglu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in drug discovery, pharmacology, and drug resistance.

ORCID

Top concepts

Publications per year

2002–2023

10

Publications

10

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Terrill K. McClanahan, Sandra Koseoglu, Kathleen B. Smith et al. · Cancer Biology & Therapy · 2006 · 181 citations · Full text

TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci

Sang Ho Lee, Hao Wang, Marc Labroli et al. · Science Translational Medicine · 2016 · 108 citations

Chemical Genomics-Based Antifungal Drug Discovery: Targeting Glycosylphosphatidylinositol (GPI) Precursor Biosynthesis

Paul A. Mann, Catherine A. McLellan, Sandra Koseoglu et al. · ACS Infectious Diseases · 2014 · 82 citations · Full text

, , +16

AKT1, AKT2 and AKT3-dependent cell survival is cell line-specific and knockdown of all three isoforms selectively induces apoptosis in 20 human tumor cell lines

Sandra Koseoglu, Zhuomei Lu, C. Chandra Kumar et al. · Cancer Biology & Therapy · 2007 · 78 citations · Full text

Transforming Growth Factor-β2 Is a Transcriptional Target for Akt/Protein Kinase B via Forkhead Transcription Factor

Ahmed A. Samatar, Luquan Wang, Asra Mirza et al. · Journal of Biological Chemistry · 2002 · 43 citations · Full text

Rows per page

1–5 of 10